Head and Neck Cancer Drug Development Summit

Memo

The Head and Neck Cancer Drug Development Summit has been curated with the industry in mind. Development in the head and neck cancer space has entered the most active period to date, with emerging immunotherapy biotechs, leading biopharma companies, and pioneering academics racing to exploit this immunogenic tumor, validate early clinical data from broader solid tumor trials, and improve clinical outcomes in this indication with a high unmet medical need. Join the only dedicated forum tackling critical challenges in head and neck cancer including: -Analyzing the role of the tumor in pathogenesis and treatment response-Understanding the mechanisms of inherent and acquired resistance -Discovering where promising avenues for targeted drug approaches for both HPV-positive and -negative subtypes are-Uncovering how we can tailor the treatment journey to leverage the advantages of HPV-specific immunotherapy, immune checkpoint inhibitors, chemoradiotherapy, and improve patient outcomes Download the full event guide to learn more about our expert speaker faculty and all agenda topics to be covered at this year's summit https://ter.li/nilxm1 URLs:Brochure: https://go.evvnt.com/842127-0?pid=5569Tickets: https://go.evvnt.com/842127-2?pid=5569 Date and Time: On Tue, Nov 30, 21 ( 9:00 AM) - Wed, Dec 1, 21 ( 3:00 PM) Prices:Industry Rate - Early Bird 1 Pricing (save $500): USD 1599.00,Industry Rate - Final Price: USD 2099.00,Solution Provider Rate - Early Bird 1 Pricing (save $700): USD 1899.00,Solution Provider Rate - Final Price: USD 2599.00 Speakers: Lars Birgerson, Chief Executive Officer, Adlai Nortye, Sophia Randolph, Chief Medical Officer, Alexo Therapeutics Inc., Michael Needle, Chief Medical Officer, AVEO Oncology, Ahmed Tajmohame, Researcher, Beacon Targeted Therapies, Anish Suri, Chief Scientific Officer and President, Cue Biopharma, Jon Wigginto, Chief Medical Officer Portfolio, Cullinan Oncology, Frederic Triebel, Chief Scientific Officer and Chief Medical Officerm Immutep, Jessica Sorrentino, Senior Director Translational Medicine, Istari Oncology, Anthony Sale, CEO, MiRecule Inc., Marshall Posner, Professor - Medicine, Mount Sinai School of Medicine, Mary Tagliaferri, SVP and Executive Clinical Fellow, Nektar, Miguel Garcia-Guzman, Chief Scientific Officer, Rakuten Medical, Maire-Louis, Fjaellskog Chief Medical Officer, Sensei Bio, Jens Bjorheim, Chief Medical Officer, Ultimovacs, Siri Torhaug, Chief Medical Officer, Vaccibody, Terrance Fisher, VP Clinical Science, VaccineX, Jan Davidson, Chief Medical Officer, Wugen Inc.